2. Outline
• Biology of aging
▫ Immunosenescence
• Epidemiology
• Pathogenesis
• Risk factor
• Special characteristics of asthma in elderly
▫ Asthma VS COPD
• Diagnosis
• Management
3. Biology of aging
• Aging is natural process and not a disease
▫ Aging lung
aging process may be contributing factor to
deterioration of lung function with progressive age
▫ Proinflammatory condition associated with
dysregulated immune system
▫ Play significant role in pathogenesis of many
chronic inflammatory diseases eg. Alzheimer’s
dementia, cardiovascular disease, type 2 DM
Current Opinion in Pulmonary Medicine 2010, 16:55–
4. Immunosenescence
• changes in the innate and adaptive immune response
associated with increased age
• Increased susceptibility to infection, malignancy and
autoimmunity, decreased response to vaccination, and
impaired wound healing
• facilitate persistence of asthma into late adulthood or
development of asthma after the age of 50 to 60 years
J Allergy Clin Immunol 2010;126:690-9.
5. Age-related changes in innate immunity
Cell type Changes with aging
Epithelial cells Decreased ciliary beat frequency and clearance
Microtubular disarrangements
Dendritic cells Reduced phagocytosis and pinocytosis
Increased IL-6 and TNF-α production
Diminished TLR expression and function
Monocytes/macrophages Reduced phagocytosis
Reduced MHC clas II expression
Reduced cytokine and chemokine secretion
Reduced generation of NO and superoxide
J Allergy Clin Immunol 2010;126:690-9.
Clinical immunology, Principles and Practice.Third edition.
6. Age-related changes in innate immunity
Cell type Changes with aging
Neutrophils Reduced phagocytosis ,bactericidal activity
Reduced chemotaxis
Reduced ROS production
NK cells Increased numbers
Reduced cytotoxicity
Reduced proinflmmatory cytokine and chemokine
production
Reduced proliferative response to IL-2
NKT cells Reduced numbers
Reduced proliferation
Eosinophils Reduced degranulation
Reduced superoxide production
J Allergy Clin Immunol 2010;126:690-9.
Clinical immunology, Principles and Practice.Third edition.
7. Age-related changes in adaptive immunity
Cell type Changes with aging
T cells Reduced Naïve T cell count
Increase memory and effector T cell count
Reduced response and proliferation
Reduced CD28 expression
Accumulation of CD8+CD28+ T cells
Reduced TCR diversity
Reduced signal transduction
B cells Reduced generation of B cell precursors
Increase No. of B1 cells
Reduced BCR diversity
Reduced size and number of GC
Reduced expression of co-stimulatory molecule
Reduced Ab affinity, Isotype switch, Ab specific to foreign Ag
Increase Ab specific to self-Ag
J Allergy Clin Immunol 2010;126:690-9.
Clinical immunology, Principles and Practice.Third edition.
8. Role of immunosenescence on features of asthma.
potential mechanism and clinical effect of immunosenescence on long-
term asthma, late-onset asthma, and asthma exacerbations in the
elderly
J Allergy Clin Immunol 2010;126:690-9.
9. Prevalence of asthma in the US among different age groups.
Data are from the 1999 National Health Interview Study
Drugs & Aging 2000 Nov; 17 (5):385-397.
10. Epidemiology
• In 2004, the US prevalence of asthma for those 65 years
or older was 7%, with 1,088,000 reporting an asthma
attack in the previous 12 months.
• Older asthmatic patients are more likely to be
underdiagnosed, undertreated and hospitalized than
younger
• highest death rate (51.3 per million people) of any age
group .
• Older women are hospitalized more than twice as often
as older men
Current Opinion in Pulmonary Medicine 2010,16:55–59
11. Asthma mortality rates by age, per 1,000,000, age-
adjusted to the 1970 Standard Million
The American Journal of Medicine, Vol 122, No 1, January 2009
14. Potential mechanisms for asthma phenotypes in the elderly
long-standing asthma late-onset asthma
Age of onset
(years)
Child or young
adult (<40)
Adult (>40)
Genetic role Likely gene by environment Likely epigenetic, including oxidative
stress and shortened telomeres
Infection Viral – rhinovirus and RSV Viral – RSV, influenza and bacterial
(e.g. Chlamydia pneumoniae),
microbial superantigens
Allergy Likely Unlikely
Inflammation Th2 driven, eosinophilic Th1 or Th2 driven, neutrophilic and/or
eosinophilic, innate immunity, Th-17,
Proteases
Environment Allergens, daycare,
school and workplace
Workplace, dwelling type (house,
apartment and Institutional)
Current Opinion in Pulmonary Medicine 2010,16:55–59
15. Pathogenesis
• Airway inflammation plays a major role in asthma
including AIE
• IL-6, prominent in older adults with generalized
inflammation, may increase IL-17 and decrease Treg
cells, resulting in predominately neutrophilic
inflammation in the lungs
• Resistance of different inflammatory cells to initiate
apoptosis in asthmatic patients, causing persistence of
airway inflammation
Current Opinion in Pulmonary Medicine 2010, 16:55–59
16. Risk factor
• Genes, and especially epigenetic changes
• Respiratory infections
▫ viral [rhinovirus and RSV]
▫ bacteria
▫ Superantigen (staphylococcal enterotoxins)
• Atopy
• Obesity
▫ increased inflammation and may cause mechanical
impairment of diaphragm excursion
• Female sex
▫ prevalence, hospitalization and higher death rates
Current Opinion in Pulmonary Medicine 2010,16:55–59
17. Studies examining early versus late-onset asthma
Current Opinion in Pulmonary Medicine 2010,16:55–59
18. Special characteristics of asthma in elderly
• Lung function decreases with age, and decrease
greater in men
• reduced response to bronchodilators and
glucocorticoids
• Rarely IgE mediated, and often develops with
component of irreversible airway obstruction
• immunosenescence
▫ Naive T cells decrease, memory T cells increase, and
B-cell function decreases, but lesser decrease in
innate immunity
▫ Eosinophil function remains the same, but neutrophil
numbers increase
J Allergy Clin Immunol 2010;126:681-7.
19. Age-related decline in FEV1 by strata in men aged 18–80 years
derived from linear mixed effects models
Mean FEV1 is corrected for height, weight, and age at first survey
Am J Respir Crit Care Med Vol 171. pp 109–114, 2005.
20. Special characteristics
of asthma in elderly
1. great variability in the
duration and severity of the
disease
2. onset can have been at
any time since childhood
but more often begins in
middle age or later
3. many of these patients
have severe irreversible
obstruction unrelated to the
duration of the diseaseThese patients are random selection
of approximately 1,200 patients 65
years of age or older given diagnosis
of asthma at Mayo Clinic in 1993
J Allergy Clin Immunol 2010;126:681-7.
21. Special characteristics of asthma in elderly
• Coexistence of asthma and COPD in elderly
patients due to
▫ Cigarette smoking
▫ Exposure to airborne endotoxin
▫ Latent adenovirus in respiratory epithelial cells
J Allergy Clin Immunol 2010;126:681-7.
22. Non-proportional Venn diagram of chronic obstructive pulmonary
disease (COPD)
Thorax. 2008 September ; 63(9): 761–767.
23. Asthma and COPD
Asthma-specific feature COPD specific feature
• Reversibility
• Airway inflammation (E )
• Th2-cytokine pattern
• Reduced elastic recoil due to
edema
• Perfusion of underventilated
areas (esp. during
exacerbation)
• Irreversible airflow
obstruction (predominantly)
• Destruction of alveoli
• Reduced elastic recoil due to
loss of lung tissue
• Ventilation of underperfused
area
• Response to anticholinergic
agents
Clinical immunology, Principles and Practice.Third edition.
Common feature
- Airflow obstruction
- Shift of tidal breathing towards TLC during exacerbation
25. Percentage of adults (by gender) with airflow obstruction who have an
overlap syndrome with increasing age. Males are shown in the black bars and
females in the white bars
Thorax 2009;64:728–735.
26. Differentiating features of COPD and asthma
COPD Asthma
(early-onset)
Asthma (late-
onset)
Overlap
syndrome
Onset Mid life Early life 65 y or older May have history
of asthma in early
life
Risk factors Smoking Atopy, airway
hyperresponsiven
ess
Atopy, irritant
exposures
Smoking, aging
Symptoms Slowly progress Intermittent, worse
at
night/morning
Intermittent, poor
perception of
symptoms
Slowly
progressive
Family history May be present Frequently
present
May be present May be present
FEV1/FVC <70% ≥70% <70% <70%
FEV1% predicted <80% >80% <80% <80%
Bronchodilator
response
Absent present present Absent
J Allergy Clin Immunol 2010;126:702-9.
27. Diagnostic challenges of asthma in the elderly
• confused with COPD and heart failure
• Spirometry
▫ underutilized in primary care setting
▫ parameters define asthma in aging population
▫ performance of effective testing
• postbronchodilator PFT
• Alterations in perception of airway obstruction due to
aging
▫ underestimation of disease severity and delay in seeking advice
• Several systemic comorbidities may coexist with AIE
Current Opinion in Pulmonary Medicine 2010,16:55–59
28. Diagnostic details that affect management after the
diagnosis of asthma has been established
• Age at onset
• Upper airway disease, sinusitis, and polyps
• ADR
▫ Aspirin, beta blocker, including eyedrops, and ACEI
• Coexisting diseases
• Pack-years of cigarette smoking or passive exposure
• Past or present occupational exposures
• Domestic exposures to irritants, allergens, and
stimulants of innate immunity
• Persistent airway obstruction despite therapy
• Total and specific IgE levels
• Abnormal chest radiographic or CT scan results
J Allergy Clin Immunol 2010;126:681-7.
29. Management challenges of asthma in the elderly
• Physicians overlooking appropriate treatment of asthma
• Patient do not want to or cannot afford to take
‘prophylactic’ or preventive medicines
• psychomotor and cognitive disabilities affect choice of
inhaler delivery systems
• drug interactions and increased incidence of ADRs
• lack of many drug trials involving elderly asthma
Current Opinion in Pulmonary Medicine 2010,16:55–59
30. Details of asthma control important in elderly
patients
• Control exposure to environmental agents
• Monitor skill of inhaling aerosol medications
• Establish ‘‘personal best’’ FEV1
• Add oral medications, such as leukotriene antagonists or
low-dose theophylline, for patients with severe asthma
• If there is a concern about cardiotoxicity of b-adrenergic
agonists, substitute anticholinergic aerosols
• Manage osteoporosis and other coexisting diseases
• Influenza and pneumococcal immunization
J Allergy Clin Immunol 2010;126:681-7.
35. SMART trial
• possible link between LABA and respiratory-related
deaths in asthmatic patients >12 yr ( mean 40)
• subjects using LABA without ICS compared with
placebo, occurred primarily in African Americans
• respiratory-related deaths
▫ (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41)
• asthma-related deaths
▫ (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34)
• combined asthma-related deaths or life-threatening
experiences
▫ (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89)
CHEST 2006; 129:15–26.
36. Anticholinergic Medications
• Cochrane review (22 studies)1
▫ statistically significant improvements in daytime dyspnea and peak
flow measurements in patients treated with inhaled anticholinergic
agents compared with placebo
▫ no difference between anticholinergic plus SABA and SABA alone in
the improvement of symptoms or PEF (maintenance Rx)
• Meta-analysis (23 RCT)2
▫ Reduction in hospitalization and improved spirometric function with
combination therapy when compared with SABA alone
• asthma guidelines recommend combining inhaled
ipratropium with SABA therapy in moderate or severe
asthma exacerbations
1.Cochrane Database Syst Rev. 2004;3:CD003269
2.Thorax. 2005;60:740-746.
37. Corticosteroids
• Adult patients with asthma did not sustain a significant
loss of BMD from ICS use1
▫ Adverse effects may be seen only after many years of high-dose
inhaled corticosteroid use
• study of 38,325 (age>66) more using ICS or INCS2
▫ increased risk of ocular HT and open-angle glaucoma with
prolonged administration (OR 1.44; 1.01-2.06)
• study of 3677 patients (aged >70) inhaled
beclomethasone or budesonide ( 1mg/d, >2 yrs.)3
▫ increased risk for cataracts (OR 3.40; 1.49-7.76)
1. CHEST 2003; 124:2329–2340
2. JAMA. 1997;277:722-727
3. JAMA. 1998;280:539-543.
38. Leukotriene Receptor Antagonists
• ACCEPT trial
▫ 4-week open-label trial of zafirlukast that included
321 asthmatic patients (aged >66)
▫ statistically significant improvements in symptoms
and morning PEF with zafirlukast, ( less than in
younger groups )
▫ Side effects in seniors were only slightly more
common than in younger adults (17.5% vs 18.8%)
Ann Allergy Asthma Immunol 2000;84:217–225.
39. Anti-immunoglobulin-E Therapies
• 2511 asthmatic patients aged 6 to 75 years
▫ Omalizumab use was associated with a reduction of
asthma exacerbations by 38% and emergency
department visits by 47%
▫ subgroup analysis showed beneficial effects among all
age groups, improvements in patients aged > 65 years
did not reach statistical significance
Allergy 2005: 60: 302–308
43. Take home message
• Asthma in elderly
▫ Underdiagnosis and undertreatment
▫ Multidimentional aspects of aging, disease
concurrence and comorbidity and patient
preference
Notas del editor
anatomic and physiologic changes seen in asthma have also been described in the
The US population over the age of 65 years is projected to grow from about 40 million in 2005
asthma in the elderly, is handicapped by the difficulty of identifying appropriate subjects
based on physicians’ diagnoses or on patients’ recollections. Physicians are often reluctant to make the diagnosis, and the accuracy has varied over time and in different locations. include subjects who have only asthma and exclude those who have coexisting lung diseases.
Data about death from asthma are conflicting. Death certificates are often inaccurate
(group 1: 65 years or older, n = 50) with younger patients (group 2: !40 years, n = 99)
group A: onset before 40, n = 22) were compared with patients developing symptoms later in their lives (group B: onset after 40, n = 22).
The roles of different inflammatory pathways and mediators of inflammation described in asthma have not been well studied in the elderly with asthma
staphylococcal enterotoxins can amplify airway inflammation and thus may have an important role in the pathogenesis and progression of asthma
Allergies are commonly associated with LSA, but much less likely to be associated with LOA
Older age of onset is associated with less allergy sensitization.
allergy tests in older patients do not seem to correlate well with nasal provocation studies or the presence of allergens in the home environment
The reasons for the decrease include stiffening of the chest wall, reduced respiratory muscle function, and an increase in residual volume from loss of elastic recoil.
The values are the best recorded after inhalation of b-adrenergic bronchodilator and are not necessarily the best that could have been obtained after a course of systemic glucocorticoid treatment. The duration of asthma was dated from the first physician’s diagnosis or the first symptoms of wheezing and shortness of breath, whichever came first. There was no difference in the results of patients who received primary care at Mayo Clinic and those referred from other cities. Only 32% of these patients had FEV1 after bronchodilator of greater than 60% of predicted normal value, and 20% had FEV1 of less than 50% of predicted normal value
Reversible AO,reversible airflow obstruction with improvement in FEV1 after bronchodilator;
irreversible AO, incompletely reversible airflow obstruction, postbronchodilator FEV1 is <80%;
irreversible AO+BDR,incompletely reversible airflow obstruction with significant bronchodilator responsiveness (BDR);
irreversible AO+BHR, incompletely reversible airflow obstruction with significant bronchial hyperresponsiveness with fall in FEV1 after bronchoconstrictor. The label ‘asthma’ can be applied to reversible AO,irreversible AO+BDR and irreversible AO+BHR.
Chronic obstructive pulmonary disease (COPD) can be applied to each of the conditions with irreversible AO+BHR.
Overlap syndrome is present in irreversible AO+BDR and irreversible AO+BHR.
The subsets comprising COPD are shaded. Subset areas are not proportional to the actual relative subset sizes.
Asthma is by definition associated with reversible airflow obstruction although, in variant asthma, special manoeuvres may be necessary to make the obstruction evident. Patients with asthma whose airflow obstruction is completely reversible (subset 9) are not considered to have COPD. Because in many cases it is virtually impossible to differentiate patients with asthma whose airflow obstruction does not remit completely from persons with chronic bronchitis and emphysema who have partially reversible airflow obstruction with airway hyperreactivity, patients with unremitting asthma are classified as having COPD (subsets 6, 7 and 8). Chronic bronchitis and emphysema with airflow obstruction usually occur together (subset 5), and some patients may have asthma
associated with these two disorders (subset 8). Individuals with asthma who have been exposed to chronic irritation, as from cigarette smoke, may develop chronic productive cough, which is a feature of chronic bronchitis (subset 6). Persons with chronic bronchitis and/or emphysema without airflow obstruction (subsets 1, 2 and 11) are not classified as having COPD. Patients with airway obstruction due to diseases with known aetiology or specific pathology such as
cystic fibrosis or obliterative bronchiolitis (subset 10) are not included in this definition.
spirometry, which are essential to diagnose airway obstruction in this population, continues to be underutilized in the primary care setting. Even when these
tests are utilized, confusion exists as to what physiologic parameters define asthma in the aging population
Thirteen single-dose trials and 20 longer duration trials
single-dose trials, seven were of asthma, five were on COPD and one reported data on both. mean age of 56.6 years
14 were of asthma and 6 were of COPD
Mean age of 52.2 years in these trials, which ranged in duration from 3 days to 1 year with a mean trial duration of 4.7 months
For trials lasting from 3 days to 1 year, 2-agonist treatment
Mean age 40 yr for SMART increase re
none of which included only seniors
no controlled trials confirming the benefits of inhaled maintenance corticosteroid therapy in elderly asthmatic patients
Current users of high doses of inhaled steroids prescribed regularly for 3 or more months were at an increased risk with an OR of 1.44 (95% confidence interval, 1.01-2.06).
Irrespective of device selection, the practitioner must demonstrate the technique, and provide regular assessment and instruction.
Minimisation of polypharmacy of inhaler devices is recommended. pMDI=pressurised metered dose inhaler. DPI=dry powder inhaler
Multidimensional assessment is represented by the spokes of the wheel and the multidisciplinary intervention by
the outer rim of wheel. LABD=long acting bronchodilator. WAP=written action plan